deCODE Genotyping Laboratory Receives College of American Pathologists Accreditation
20 Mai 2009 - 4:25PM
PR Newswire (US)
Underscores Quality of deCODE's Laboratory and Tests, Fulfilling
Key Federal and State Certification Requirements and Broadening
Marketing Channels REYKJAVIK, Iceland, May 20
/PRNewswire-FirstCall/ -- deCODE genetics (NASDAQ:DCGN) today
announced that its CLIA-registered DNA isolation and genotyping
laboratory, which processes the company's deCODEme(TM) personal
genome scans and risk assessment diagnostic tests for several
common diseases, has been accredited by the American College of
Pathologists (CAP) following a recent inspection. The U.S. Centers
for Medicare and Medicaid Services (CMS) has granted the CAP
Laboratory Accreditation Program deeming authority, and its
accreditations can also be used to meet many state certification
requirements. "We believe that testing for genetic risk factors for
common diseases is going to play a central role in refocusing our
healthcare system on prevention and early intervention. deCODE has
led the way in discovering validated genetic risk factors for
diseases with a major impact on public health, and in bringing to
market products that put this knowledge in the hands of individuals
and their doctors. Quality - in our world-leading science and
in-house genotyping and data analysis - sets us apart from our
competition in the field of personal genomics. CAP certification
serves to emphasize this advantage and will enable us to provide
our products to an ever wider public," said Kari Stefansson, CEO of
deCODE. The CAP Laboratory Accreditation Program, begun in the
1960s, is an internationally recognized program for certifying
laboratory quality based upon inspections conducted by practicing
laboratory professionals. CAP inspectors examine a laboratory's
records and quality control of precedures for the preceding two
years; the qualifications of all staff; equipment and facilities;
safety program and record; and overall management. The inspections
program is designed to ensure the highest standard of care for all
laboratory patients. About the College of American Pathologists The
College of American Pathologists (CAP) is a medical society that
serves more than 17,000 physician members and the laboratory
community throughout the world. It is the world's largest
association composed exclusively of pathologists and is widely
considered the leader in laboratory quality assurance. The CAP is
an advocate for high quality and cost effective medical care. About
deCODE deCODE is a bio-pharmaceutical company developing drugs and
DNA-based tests to improve the treatment, diagnosis and prevention
of common diseases. Its lead therapeutic programs, which leverage
the company's expertise in chemistry and structural biology,
include DG041, an antiplatelet compound being developed for the
prevention of arterial thrombosis; DG051 and DG031, compounds
targeting the leukotriene pathway for the prevention of heart
attack; and DG071 and a platform for other PDE4 modulators with
therapeutic applications in Alzheimer's disease and other
conditions. deCODE is a global leader in human genetics, and has
identified key variations in the genome (SNPs) conferring increased
risk of major public health challenges from cardiovascular disease
to cancer. Based upon these discoveries deCODE has brought to
market a growing range of DNA-based tests for gauging risk and
empowering prevention of common diseases. Through its
CLIA-registered laboratory, deCODE offers deCODE T2(TM) for type 2
diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE
MI(TM) for heart attack; deCODE ProstateCancer(TM) for prostate
cancer; deCODE Glaucoma(TM) for a major type of glaucoma; and
deCODE BreastCancer, for the common forms of breast cancer. deCODE
is delivering on the promise of the new genetics.SM Visit us on the
web at http://www.decode.com/; on our diagnostics site at
http://www.decodediagnostics.com/; for our pioneering personal
genome analysis service and new focused disease scans, integrating
the genetic variants included in these tests and those linked to
another twenty common diseases, as well as for our new deCODEme
Cardio(TM) and deCODEme Cancer(TM) scans, at
http://www.decodeme.com/; and on our blog at
http://www.decodeyou.com/. Any statements contained in this
presentation that relate to future plans, events or performance are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are subject to a number of risks and uncertainties that
could cause actual results, and the timing of events, to differ
materially from those described in the forward-looking statements.
These risks and uncertainties include, among others, those relating
to our ability to obtain sufficient financing to continue as a
going concern, the outcome of the review of the continued listing
of our common stock on The Nasdaq Stock Market, our ability to
develop and market diagnostic products, the level of third party
reimbursement for our products, risks related to preclinical and
clinical development of pharmaceutical products, including the
identification of compounds and the completion of clinical trials,
our ability to form collaborative relationships, the effect of
government regulation and the regulatory approval processes, market
acceptance, our ability to obtain and protect intellectual property
rights for our products, dependence on collaborative relationships,
the effect of competitive products, industry trends and other risks
identified in deCODE's filings with the Securities and Exchange
Commission, including, without limitation, the risk factors
identified in our most recent Annual Report on Form 10-K and any
updates to those risk factors filed from time to time in our
Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.
deCODE undertakes no obligation to update or alter these
forward-looking statements as a result of new information, future
events or otherwise. Contacts: deCODE genetics Edward Farmer
+44-7796-010107 Gisli Arnason +354-570-1900 Joy Bessenger
+1-212-481-3891 DATASOURCE: deCODE genetics Inc CONTACT: Contacts:
deCODE genetics, Edward Farmer, +44-7796-010107, ; Gisli Arnason,
+354-570-1900, ; Joy Bessenger, +1-212-481-3891,
Copyright
Decode Genetics (MM) (NASDAQ:DCGN)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Decode Genetics (MM) (NASDAQ:DCGN)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024